Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study

Núria Fabrellas1,2,3*, Rosario Hernández4*, Isabel Graupera2,3,5, Elsa Solà2,3,5, Pilar Ramos5, Natividad Martín4, Gemma Sáez4, Consuelo Simón4, Almudena Pérez4, Teresa Graell6, Andrea Larrañaga4, Manel García4, Ana de la Arada4, Adrià Juanola2,3,5, Alicia Coiduras4, Isabel Duaño2, Angel Casado4, Julian Martín4, Marta Ginès4, Nuria Moreno4, Ana Gema Perez4, Laia Martí4, Mireia Bernat4, Montse Solà4, Carmina Olivé1, Cristina Solé2,3,5*, Pere Ginès2,3,5*

1 School of Medicine and Health Sciences, University of Barcelona, Barcelona, Catalonia, Spain, 2 Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalonia, Spain, 3 Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHID), Barcelona, Catalonia, Spain, 4 Centre d’Assistència Primària La Marina, Institut Català de la Salut (ICS), Barcelona, Catalonia, Spain, 5 Liver Unit, Hospital Clinic, University of Barcelona, Barcelona, Catalonia, Spain

* pgines@clinic.cat

Abstract

Background

Primary care is the ideal setting for early identification of patients with non-alcoholic fatty liver disease (NAFLD). NAFLD is a potentially progressive disease that may lead to cirrhosis and liver cancer but is frequently underrecognized because subjects at risk are often not evaluated. Controlled attenuation parameter (CAP) is a reliable method for non-invasive quantification of liver fat. It has the advantage of simultaneous measurement of liver stiffness (LS), an estimate of liver fibrosis. There is no information on CAP in subjects with risk factors from primary care.

Aim

To investigate the prevalence of hepatic steatosis, as estimated by CAP, in subjects from the community with metabolic risk factors and correlate findings with clinical and biochemical characteristics and LS.

Patients and methods

Population-based study of 215 subjects with metabolic risk factors without known liver disease identified randomly from a primary care center. A control group of 80 subjects matched by age and sex without metabolic risk factors was also studied. CAP and LS were assessed using Fibroscan.
the confirmation of the Ethics Committee. The president of the Ethics Committee has specifically stated the request to be made through the principal investigator of the study and not through the Ethics Committee itself.

Funding: The study was supported by grants from the Instituto de Salud Carlos III through the Plan Estatal de Investigación Científica Y Técnica y de Innovación 2013-2016, project reference PI 12/00330 and PI 16/00043 to PG. This grant was co-funded by the European Regional Development Fund (ERDF). The study is also supported by the Agencia de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) 2014/SGR 708. PG is a recipient of an ICREA Academia Award. In addition, this study was funded by the European Institute of Innovation and Technology grant no. 18258 to PG. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: Pere Ginés declares he has received research funding from Grifols S.A, Ferring Pharmaceuticals, Sequana. He has consulted for Mallinckrodt, Intercept, Sequana, Ferring and Grifols. This does not alter the authors’ adherence to PLOS ONE policies on sharing data and materials. No other authors have any competing interests.

Results
Subjects with risk factors had CAP values higher than those of control group (268±64 vs 243±49dB/m, p<0.001). Prevalence of severe steatosis (CAP> 280dB/m) in subjects with risk factors was 43%. In multivariate analysis, fatty liver index (FLI) and HOMA were independent predictive factors of severe steatosis. There was a direct correlation between CAP and FLI values (r = 0.52, p<0.001). Interestingly, prevalence of increased LS was 12.6% in the risk group vs 0% in the control group (p<0.001). Increased LS occurred predominantly in subjects with high CAP values.

Conclusions
A high proportion of subjects with metabolic risk factors seen in primary care have severe steatosis. FLI could be used as a surrogate of CAP. Increased LS was found in a significant proportion of subjects with risk factors but not in control subjects.

Introduction
Non-alcoholic fatty liver disease (NAFLD) is a major health problem worldwide because of its high prevalence and its important long-term morbidity and mortality [1–5]. NAFLD affects approximately 25% of the population worldwide and its incidence is growing rapidly because of associated metabolic comorbidities, such as obesity, type-2 diabetes, hyperlipidemia, and metabolic syndrome, the frequency of which is increasing at a very fast rate in most areas of the world [1–3]. The presence of fat in the liver is associated with an increased risk of liver-related morbidity and mortality through development of liver fibrosis and cirrhosis [6,7]. Moreover, patients with NAFLD have decreased survival compared to that of the general population due to cardiovascular complications, development of cirrhosis, and hepatic as well as non-hepatic tumors [5,8,9].

The diagnosis of NAFLD relies on the demonstration of presence of hepatic steatosis in the absence of secondary causes of fat accumulation such as significant alcohol consumption, use of certain drugs or hereditary disorders [10,11]. The ideal setting for the diagnosis of NAFLD is primary care because patients with risk factors for NAFLD are usually seen in the community by primary physicians or nurse practitioners caring for their metabolic comorbidities. The most commonly used method for diagnosis of hepatic steatosis in the community is liver ultrasonography because it is simple and widely available. However, liver ultrasonography has several drawbacks, particularly limited sensitivity, difficulty in the morbidly obese, it is operator dependent, only provides qualitative or semi-quantitative information about the amount of fat, and is not useful for the detection of concomitant liver fibrosis [12]. In NAFLD, liver fibrosis is important because its presence and severity predicts cirrhosis development and long-term survival [9,13,14]. Other methods to estimate the amount of fat in the liver such as proton magnetic spectroscopy or serum biomarkers, such as fatty liver index (FLI), Steatotest®, and NAFLD fibrosis score, are generally not used in primary care [11,12].

Controlled attenuation parameter (CAP) is a system that measures the degree of ultrasound attenuation by hepatic fat using a process based on vibration control transient elastography [12]). A number of studies have demonstrated that CAP has high predictive accuracy of the amount of fat in the liver, particularly in patients with NAFLD [15–17]. Therefore, CAP is currently considered a precise noninvasive method for assessment of hepatic fat. Moreover, CAP
has the additional advantage of the simultaneous evaluation of liver fibrosis by measurement of liver stiffness (LS). [12]

Although there are numerous studies evaluating CAP in large series of patients with NAFLD in tertiary hospitals, there is little information on the application of CAP in primary care [18]. Particularly, there is no information on the use of CAP in assessment of hepatic steatosis in subjects with metabolic risk factors in the community. In the current study, we used CAP to assess the prevalence of hepatic steatosis in patients with metabolic risk factors identified randomly in a primary care center. The prevalence was compared to that of a control group of subjects without metabolic risk factors. CAP values were correlated with clinical and biochemical variables and also with LS.

**Patients and methods**

**Aims**

The current study was aimed at investigating the prevalence of steatosis as assessed by CAP in subjects from the community setting with metabolic risk factors but without known liver disease. Secondary objectives were: 1) to compare the prevalence of steatosis in subjects with metabolic risk factors with that of a control group of similar age and sex without metabolic risk factors; and 2) to correlate CAP values with clinical and biochemical characteristics as well as LS.

**Population and study protocol**

This is a population-based, cross-sectional study that included 215 subjects with metabolic risk factors but without known liver disease from the community setting. Subjects were recruited from primary care center La Marina (Barcelona) and considered eligible for participation in the study if they had at least one of the following metabolic risk factors, as reported elsewhere [10]: 1) obesity; 2) type-2 diabetes mellitus; 3) dyslipidemia; and 4) metabolic syndrome, as defined by presence of 3 or more of the following features: a) waist circumference greater than 102 cm in men or 88 cm in women; b) serum triglycerides ≥150 mg/dL; c) high-density lipoprotein (HDL) cholesterol levels less than 40 mg/dL in men or less than 50 mg/dL in women; d) systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg; and e) fasting plasma glucose ≥110 mg/dL [19]. Subjects aged >18 yr were identified using computer-generated random numbers from the patient registry that contains clinical information of citizens assigned to the primary care center using metabolic risk factors shown above as keywords. Patients with known diagnosis of liver disease were excluded. Other exclusion criteria were active malignancy, severe chronic conditions, and admission in nursing homes. Eligible subjects were then contacted by telephone by nurses or general practitioners from the primary care center and invited to participate in the study. Subjects interested were invited to attend the primary care center where a member of the research team explained carefully the objectives of the investigation and the study protocol (Fig 1).

Patients who accepted signed a written informed consent. At the visit in the primary care center, demographic and clinical data were collected from all participants. Weight, height, waist circumference, and arterial pressure were measured. In addition, a blood sample was taken to determine standard liver tests, lipid profile, serum ferritin, serum creatinine, glycated hemoglobin, and fasting insulin levels. FLI was calculated using standard formula [20]. In all subjects, CAP and LS were measured (see later). Subjects with LS >7 kPa with the M probe or >6.2 kPa with the XL probe, were referred to the Liver Unit of the Hospital Clinic of Barcelona for hepatology consultation, which consisted of assessment of liver disease following a diagnostic protocol that included disease assessment and staging with liver tests, liver
ultrasonography, and liver biopsy in patients who accepted the procedure. Subjects with LS < 7 or 6.2 with the M and XL probes, respectively, did not undergo further evaluation. These cutoffs were selected on the basis of those used in previous studies [21–23]. A control group of subjects matched (2:1) by sex and age (±5 years) with those of the study group, but without metabolic risk factors was studied for comparison. Subjects for the control group were selected among subjects attending consultations of primary care physicians. Of the 110 subjects who accepted to participate, 30 subjects were subsequently excluded because metabolic risk factors were identified during study assessment (n = 24) or alcohol risk consumption (n = 6). Therefore, the control group consisted of 80 subjects. The protocol was approved by the Investigational Review Boards of the primary care center (Fundació Gol i Gorina) and Hospital Clinic i Provincial of Barcelona.
CAP and liver stiffness measurements

CAP and LS measurements were performed by a single experienced operator (PR) using Fibroscan system 502 touch® (Echosens, Paris). Either M or XL probes were used. The decision to use the M or XL probes was made following the recommendation of the software of the system. The principles of CAP have been reported in detail elsewhere [12,24]. Measurements were always performed in the morning after overnight fast. CAP was computed only when LS measurement was valid and with the same signals used to measure LS. The final CAP value was the median of individual CAP values and was expressed in dB/m. In 3 of the 295 subjects included (1%), LS could not be determined (body mass index–BMI- and waist circumference in these patients were 43, 35, and 34 Kg/m2 and 140, 111, and 114 cm, respectively). The levels of CAP used to define the presence and degree of steatosis were as follows: 1/ <248dB/m, no steatosis (S0); 2/ 248–268 dB/m, mild steatosis (S1); 3/ >268 and ≤280 dB/m, moderate steatosis (S2); and 4/ >280 dB/m, severe steatosis (S3), as reported elsewhere [25]. Reliability of LS measurements using specific criteria [26] showed that all measurements performed were either reliable or very reliable (65% and 35%, respectively). No measurements had poor reliability using these criteria.

Statistical analysis

Results for continuous variables were expressed as mean and standard deviation. Counts and percentages were used for the description of the categorical variables. Comparisons between two independent groups were made with the t-test (previously checking the hypothesis of variance homogeneity) for continuous normal-distributed variables. The Mann-Whitney U test was carried out for continuous non-normal distributed variables in the case of 2 independent groups. Comparison between variables of more than 2 groups was performed with ANOVA or Kruskal-Wallis. Comparisons of categorical variables among groups were made with chi-squared test or Fisher test if appropriate. Transaminase levels have been considered classically as surrogate markers of steatosis. Therefore, the predictive accuracy of FLI in the diagnosis of severe steatosis was compared with that of AST/ALT levels using AUROC curves.

Multivariate logistic regression models were performed to assess independent predictive factors of steatosis, severe steatosis, and LS. The significance level for all statistical tests was set at 0.05 two-tailed. All statistical analyses were performed using SPSS 20.0 software.

Results

Characteristics of the study population

Comparison of the demographic, clinical, and biochemical characteristics of subjects from the risk group and control group is shown in Table 1. As expected, due to the inclusion criteria, subjects with metabolic risk factors had marked alteration of laboratory variables, such as glucose, triglycerides, HDL-cholesterol, glycated hemoglobin, and HOMA, compared to control subjects without metabolic risk factors.

Prevalence of steatosis and factors associated with CAP values

The degree of steatosis and LS were related to the presence of metabolic risk factors. Subjects with metabolic risk factors had significantly higher CAP and LS values compared to those of control subjects (268±64 vs 243±49 dB/m and 4.9±2.7 vs 4.2±0.9 kPa, respectively; p<0.01 for both) (Table 1). Moreover, the prevalence of steatosis was significantly higher in the risk factor group compared to the control group, regardless the cutoff values of CAP used for steatosis grading (Table 2).
Tables 3 to 5 show the comparison of baseline characteristics of subjects categorized into different subgroups according to the cutoff levels of CAP of 248, 268, and 280 dB/m, which allows a comparison of subjects with S0 vs S1-2-3 (Table 3), S0-1 vs S2-3 (Table 4), and S-0-1-2 vs S3 (Table 5).

Table 1. Comparison of demographic, clinical, and biochemical data, and liver stiffness and CAP of subjects from the risk group and control group.

| Variable                  | Risk group n = 215 | Control group n = 80 | P value |
|---------------------------|--------------------|----------------------|---------|
| Age (yr)                  | 58 ± 12            | 62 ± 13              | 0.03    |
| Male gender               | 35 (44%)           | 91 (842%)            | 0.9     |
| Tobacco consumption       | 45 (20%)           | 17 (19%)             | 0.7     |
| Diabetes Mellitus         | 60 (28%)           | -                    | <0.001  |
| Dyslipidemia              | 150 (70%)          | -                    | <0.001  |
| Obesity (BMI≥30 Kg/m²)    | 113 (52%)          | -                    | <0.001  |
| Metabolic syndrome        | 98 (46%)           | -                    | <0.001  |
| Number of risk factors    |                    |                      |         |
| 1                         | 86 (40%)           |                      |         |
| 2                         | 66 (31%)           |                      |         |
| ≥3                        | 63 (29%)           |                      |         |
| BMI (Kg/m²)               | 31 ± 5             | 25 ± 2               | <0.001  |
| Waist circumference (cm)  | 104 ± 13           | 91 ± 10              | <0.001  |
| Glucose (mg/dL)           | 112 ± 40           | 89 ± 10              | <0.001  |
| Total cholesterol (mg/dL) | 204 ± 44           | 198 ± 26             | 0.15    |
| HDL-cholesterol (mg/dL)   | 49 ± 14            | 58 ± 16              | <0.001  |
| LDL-cholesterol (mg/dL)   | 129 ± 33           | 123 ± 24             | <0.001  |
| Triglycerides (mg/dL)     | 138 ± 83           | 83 ± 24              | <0.001  |
| ALT (IU/L)                | 26 ± 16            | 24 ± 11              | 0.16    |
| GGT (IU/L)                | 34 ± 35            | 27 ± 40              | 0.16    |
| Serum creatinine (mg/dL)  | 0.7 ± 0.1          | 0.7 ± 0.2            | 0.6     |
| Albumin (g/L)             | 44 ± 2             | 43 ± 2               | 0.8     |
| Ferritin (ng/mL)          | 125 ± 137          | 104 ± 91             | 0.21    |
| Glycated hemoglobin (%)   | 6.2 ± 1            | 5.5 ± 0.3            | <0.001  |
| HOMA                      | 5.7 ± 8.6          | 2.2 ± 1.4            | <0.001  |
| LS (kPa)                  | 4.9 ± 2.7          | 4.2 ± 0.9            | 0.002   |
| CAP (dB/m)                | 268 ± 64           | 243 ± 49             | 0.001   |

Values are number and percentages (in brackets) or mean±SD. BMI, body mass index; ALT, alanine aminotransferase; GGT, gamma glutamyltranspeptidase; HOMA, Homeostasis model assessment; LS, liver stiffness; CAP, controlled attenuation parameter.  

https://doi.org/10.1371/journal.pone.0200656.t001

Table 2. Prevalence of steatosis in patients with (risk group) and without risk factors for NAFLD (control groups).

|                       | Risk group n = 215 | Control group n = 80 | P value |
|-----------------------|--------------------|----------------------|---------|
| CAP > 248 dB/m (S0 vs S1-2-3) | 136 (63%)          | 37 (42%)             | 0.01    |
| CAP > 268 dB/m (S0-1 vs S2-3) | 106 (49%)          | 27 (34%)             | 0.02    |
| CAP > 280 dB/m (S0-1-2 vs S-3) | 93 (43%)           | 24 (30%)             | 0.045   |

Values are numbers of subjects and percentages (in brackets)  

https://doi.org/10.1371/journal.pone.0200656.t002
The degree of steatosis was associated with diabetes mellitus, obesity, metabolic syndrome, greater BMI and waist circumference, and higher glucose, triglycerides, ALT, GGT, ferritin, glycosylated hemoglobin, and HOMA levels, and lower HDL-cholesterol. Moreover, the degree of steatosis was also associated with higher FLI values. There was a statistically significant direct correlation between CAP and FLI values ($r = 0.52$, $p < 0.001$) (Fig 2).

In multivariate analysis, factors independently associated with steatosis or severe steatosis were FLI alone or in association with HOMA, respectively (Table 6).

If FLI was not included in the multivariate analysis, variables independently associated with CAP $>$ 248 dB/m were triglycerides and BMI, and those associated with CAP $>$ 280 dB/m were triglycerides, waist circumference, and glycated hemoglobin. The direct relationship between CAP and FLI was also observed in the whole population of subjects included in the study, with and without metabolic risk factors ($r = 0.48$, $p < 0.001$).

| Variable               | CAP $<$ 248 dB/m | CAP $>$ 248 dB/m S1-2-3 |
|------------------------|------------------|------------------------|
| Age (yr)               | 63 ± 13          | 62 ± 12                | 0.7        |
| Male gender            | 30 (38%)         | 61 (45%)               | 0.4        |
| Tobacco consumption    | 12 (15%)         | 31 (23%)               | 0.4        |
| Diabetes Mellitus      | 16 (20%)         | 44 (32%)               | 0.06       |
| Dyslipidemia           | 53 (67%)         | 97 (71%)               | 0.54       |
| Obesity (BMI $>$ 30 kg/m$^2$) | 30 (38%)     | 83 (61%)               | 0.002      |
| Metabolic syndrome     | 28 (35%)         | 70 (51%)               | 0.02       |
| **Number of risk factors** |                  |                        |            |
| 1                      | 14 (18%)         | 15 (11%)               | 0.03       |
| 2                      | 29 (38%)         | 45 (34%)               |            |
| $>$ 3                   | 28               | 70 (51%)               |            |
| BMI (Kg/m$^2$)         | 29 ± 5           | 32 ± 5                 | $<0.001$   |
| Waist circumference (cm)| 100 ± 12        | 106 ± 12               | $<0.001$   |
| Glucose (mg/dL)        | 102 ± 35         | 118 ± 42               | 0.006      |
| Total cholesterol (mg/dL) | 203 ± 46     | 204 ± 43               | 0.9        |
| HDL-cholesterol (mg/dL) | 53 ± 17         | 47 ± 12                | 0.008      |
| LDL-cholesterol (mg/dL) | 129 ± 36        | 128 ± 31               | 0.9        |
| Triglycerides (mg/dL)  | 113 ± 69         | 152 ± 87               | 0.001      |
| ALT (IU/L)             | 22 ± 11          | 28 ± 17                | 0.002      |
| GGT (IU/L)             | 29 ± 30          | 38 ± 38                | 0.08       |
| Creatinine (mg/dL)     | 0.7 ± 0.3        | 0.7 ± 0.2              | 0.7        |
| Albumin (g/L)          | 44 ± 2           | 44 ± 3                 | 0.8        |
| Ferritin (ng/mL)       | 111 ± 109        | 134 ± 151              | 0.2        |
| Glycated hemoglobin (%)| 5.9 ± 0.9        | 6.3 ± 1.1              | 0.01       |
| HOMA                   | 3.5 ± 2.8        | 7.0 ± 10.4             | $<0.001$   |
| FLI                    | 52 ± 27          | 73 ± 21                | $<0.001$   |
| LS (kPa)               | 4.2 ± 1.1        | 5.3 ± 3.2              | $<0.001$   |
| CAP (dB/m)             | 204 ± 38         | 305 ± 43               | $<0.001$   |

Values are number and percentages (in brackets) or mean±SD. BMI, body mass index; ALT, alanine aminotransferase; GGT, gamma glutamyltranspeptidase; HOMA, Homeostasis model assessment; LS, liver stiffness; CAP, controlled attenuation parameter.

https://doi.org/10.1371/journal.pone.0200656.t003
As shown in Fig 3, the predictive accuracy of FLI in the diagnosis of severe steatosis was significantly better than that of AST or ALT.

The best cutoff value of FLI for the diagnosis of severe steatosis was of 96. Similar findings were observed when the whole population of subjects, with and without risk factors, was considered or when analyzing moderate/severe steatosis instead of severe steatosis (data not shown). It is important to emphasize that 84 of the 106 (79%) subjects with risk factors and moderate or severe steatosis had normal AST and ALT values.

### Liver stiffness measurement and relationship with CAP

Twenty-seven of the 215 subjects (12.6%) of the risk group had increased LS, as estimated by values greater than 7kPa or 6.2 kPa, with the M and XL probes, respectively. By contrast, none of the 80 subjects from the control group without metabolic risk factors had increased LS ($x^2 =$...
If a higher cutoff of LS was considered (>8Kpa) the prevalence of increased LS in the risk group was of 4% (9 of the 215 subjects). Factors associated with increased LS in univariate analysis were diabetes mellitus, obesity, BMI, waist circumference, glucose, ALT, glycated hemoglobin, HOMA, and CAP (Table 7).

In multivariate analysis, variables independently associated with increased LS were diabetes mellitus, waist circumference, and ALT (Table 8).

Prevalence of increased LS was significantly greater in subjects with severe steatosis (S3) than in those with mild/moderate (S1-2) or no steatosis (S0) (22% vs 5 and 6%, respectively (Fig 4). Remarkably, in the control group without metabolic risk factors, none of the subjects had increased LS regardless of CAP values (Fig 4).

Fig 5 shows the relationship between LS and CAP and LS and FLI in subjects with metabolic risk.

Table 5. Comparison of baseline characteristics of subjects with risk factors for NAFLD categorized according to the presence (S3) or absence (S0-1-2) of severe steatosis measured by CAP values.

| Variable                      | CAP < 280dB/m | CAP ≥ 280dB/m |
|-------------------------------|---------------|--------------|
|                               | S0-1-2        | S3           |
|                               | n = 122       | n = 93       |
| Age (yr)                      | 62 ± 13       | 63 ± 12      | 0.5          |
| Male gender                   | 48 (39%)      | 43 (46%)     | 0.3          |
| Tobacco consumption           | 24 (19%)      | 19 (21%)     | 0.63         |
| Diabetes Mellitus             | 25 (21%)      | 35 (38%)     | 0.009        |
| Dyslipidemia                  | 83 (68%)      | 67 (72%)     | 0.55         |
| Obesity (BMI≥30kg/m²)         | 49 (41%)      | 64 (69%)     | <0.001       |
| Metabolic syndrome            | 46 (38%)      | 52 (56%)     | 0.009        |

Number of risk factors

| 1 | 0.003 |
| 2 |       |
| >3|       |

BMI (Kg/m²) | 0.001
Waist circumference (cm) | <0.001
Total cholesterol (mg/dL) | 0.18
HDL- cholesterol (mg/dL) | <0.001
LDL-cholesterol (mg/dL) | 0.37
Triglycerides (mg/dL) | 0.001
ALT (IU/L) | 0.006
GGT (IU/L) | 0.02
Creatinine (mg/dL) | 0.6
Albumin (g/L) | 0.9
Ferritin (ng/mL) | 0.05
Glycated hemoglobin (%) | 0.001
HOMA | 0.001
FLI | 0.001
LS (kPa) | <0.001
CAP (dB/m) | <0.001

Values are number and percentages (in brackets) or mean±SD. BMI, body mass index; ALT, alanine aminotransferase; GGT, gamma glutamyltranspeptidase; HOMA, Homeostasis model assessment; LS, liver stiffness; CAP, controlled attenuation parameter.
The 27 patients with increased LS were referred to the hospital for hepatology consultation and 22 accepted. In all 22 patients the diagnosis of NAFLD was confirmed by ultrasonography. Mean LS and CAP values in these patients were $10.0 \pm 5.9\text{kPa}$ (range 6.6–31.6) and $323 \pm 67 \text{dBm}$ (range 170–400), respectively. Nine of the 22 patients (40%) underwent a liver biopsy. LS values in patients in whom a liver biopsy was performed were $13.3 \pm 8.2 \text{kPa}$ (range 7–31.6). Histological examination showed significant liver fibrosis in 3 (F2, F3 and F4) associated with moderate steatosis, and steatosis without fibrosis in 6 patients (severe and moderate in one patient each, and mild in the remaining 4 patients).

Table 6. Multivariate Logistic Regression analysis of variables associated with steatosis and severe steatosis.

| Steatosis (CAP ≥ 248dB/m) | OR    | CI    | P value |
|---------------------------|-------|-------|---------|
| Independent Variable      |       |       |         |
| FLI                       | 1.032 | 1.019–1.046 | <0.01  |

| Severe steatosis (CAP ≥ 280dB/m) | OR    | CI    | P value |
|----------------------------------|-------|-------|---------|
| Independent Variables            |       |       |         |
| FLI                              | 1.036 | 1.02–1.052 | <0.001 |
| HOMA                             | 1.085 | 1.007–1.169 | 0.031  |

Variables included in the model for Steatosis: FLI, Triglycerides, BMI, Waist circumference, HDL-cholesterol, ALT, Glycated Hb and HOMA.

Variables included in the Severe Steatosis model: FLI, Diabetes, BMI, Waist circumference, HDL-cholesterol, ALT, Glycated Hb and HOMA.

https://doi.org/10.1371/journal.pone.0200656.t006
The results of the current study show that a high proportion of subjects with metabolic risk factors from the community, without known liver disease, have severe steatosis as indicated by high values of CAP. The degree of steatosis did not correlate with transaminase levels but showed good correlation with FLI. Increased LS, suggestive of liver fibrosis, was only found in subject with metabolic risk factors and increased CAP values.

Epidemiological studies indicate that NAFLD affects more than 25% of the adult population worldwide and is particularly common among subjects with metabolic risk factors [1–3]. Patients with NAFLD should be identified not only because they are at risk of developing liver fibrosis subsequently leading to cirrhosis and hepatocellular carcinoma, but also because they have increased mortality due to cardiovascular events [1–3]. Although hepatic steatosis without inflammation has been classically considered a “benign” condition, without risk of progression, recent studies indicate that as much as one fourth of patients with simple steatosis can progress to steatohepatitis and fibrosis within a short period of time [27,28]. Most subjects at risk for NAFLD are in the community setting and not in the hospital unless they develop
some acute complications. Therefore, identification should ideally be performed in primary care. Interestingly, it has been reported that NAFLD is frequently underrecognized in the primary care setting and subjects with metabolic risk factors are not frequently evaluated for this condition [29,30].

Along these lines, the results of the current study, in which CAP was used for evaluation of hepatic steatosis, demonstrate that 43% of adults subjects with metabolic risk factors and previously unrecognized liver disease identified randomly from primary care have severe steatosis. Previous studies have shown that other noninvasive methods to estimate hepatic steatosis, including hepatic ultrasound or transaminase levels, lack sensitivity in the detection of hepatic steatosis [12]. CAP is not a perfect method, but studies in which CAP values have been

Table 7. Comparison of characteristics of subjects with risk factors for NAFLD categorized according to liver stiffness.

| Variable                        | Normal LS N = 188 | Increased LS* N = 27 | P value |
|---------------------------------|-------------------|----------------------|---------|
| Age                             | 62 ± 12           | 65 ± 13              | 0.2     |
| Male gender                     | 76 (83%)          | 15 (16%)             | 0.15    |
| Diabetes Mellitus               | 46 (24%)          | 14 (52%)             | 0.005   |
| Dyslipidemia                    | 135 (72%)         | 15 (56%)             | 0.12    |
| Obesity (BMI ≥ 30 kg/m²)        | 94 (50%)          | 19 (73%)             | 0.03    |
| Metabolic syndrome             | 83 (44%)          | 15 (56%)             | 0.3     |
| BMI (Kg/m²)                     | 30 ± 5            | 35 ± 6               | <0.001  |
| Waist circumference (cm)        | 102 ± 11          | 115 ± 13             | <0.001  |
| Glucose (mg/dL)                 | 107 ± 34          | 146 ± 58             | 0.002   |
| Total cholesterol (mg/dL)       | 206 ± 45          | 188 ± 36             | 0.05    |
| HDL-cholesterol (mg/dL)         | 50 ± 15           | 46 ± 13              | 0.2     |
| LDL-cholesterol (mg/dL)         | 130 ± 34          | 118 ± 28             | 0.1     |
| Triglycerides (mg/dL)           | 134 ± 80          | 165 ± 97             | 0.065   |
| ALT (IU/L)                      | 25 ± 13           | 36 ± 24              | 0.02    |
| GGT (IU/L)                      | 31 ± 28           | 57 ± 69              | 0.06    |
| Albumin (g/L)                   | 44 ± 2            | 43 ± 3               | 0.6     |
| Ferritin (ng/mL)                | 115 ± 109         | 194 ± 253            | 0.1     |
| Glycated hemoglobin (%)         | 6 ± 0.9           | 6.8 ± 1.3            | 0.007   |
| HOMA                            | 4.7 ± 6.2         | 12.6 ± 16.61         | 0.03    |
| FLI                             | 63 ± 25           | 85 ± 18              | <0.001  |
| CAP (dB/m)                      | 261 ± 59          | 316 ± 71             | <0.001  |

* >7 Kpa with M probe or >6.2 kPa with XL probe.

Values are number and percentages (in brackets) or mean±SD. BMI, body mass index; ALT, alanine aminotransferase; GGT, gamma glutamyltranspeptidase; HOMA, Homeostasis model assessment; LS, liver stiffness; CAP, controlled attenuation parameter.

https://doi.org/10.1371/journal.pone.0200656.t007

Table 8. Multivariate logistic regression analysis of variables associated with increased liver stiffness in subjects with risk factors for NAFLD.

| VARIABLE                  | OR     | CI          | P value |
|---------------------------|--------|-------------|---------|
| Diabetes Mellitus         | 4.8    | 1.7–13.4    | 0.002   |
| Waist circumference       | 1.1    | 1.04–1.1    | <0.001  |
| ALT                       | 1.03   | 1.003–1.057 | 0.03    |

Variables included in the model: BMI, waist circumference, ALT, Glycated Hb and HOMA, Diabetes mellitus, CAP, FLI

https://doi.org/10.1371/journal.pone.0200656.t008
compared with liver histology, show that the AUROC curves for severe steatosis (>66% of hepatocytes) are greater than 0.8 [16]. Therefore, it is likely that the majority of subjects identified in the current study with high CAP values had severe steatosis. Unfortunately, histological confirmation is not available because liver biopsy was only performed in a small number of subjects who had increased LS. As expected from results of previous studies, CAP values correlated strongly with metabolic factors, particularly diabetes mellitus, obesity, metabolic syndrome, BMI, waist circumference, glucose, LDL-cholesterol, triglycerides, ALT, glycated hemoglobin, and HOMA [15–18].

Another interesting observation of the current study was the existence of a direct correlation between CAP and FLI values. Remarkably, in multivariate analysis, FLI was an independent predictive factor of steatosis and severe steatosis. This strong direct correlation found is probably related to the fact that the four components of FLI (BMI, waist circumference, triglycerides, and GGT) are strongly related to metabolic syndrome [20]. Our findings confirm previous observations in subjects from the general population [18]. Altogether, these findings suggest that FLI can be used as a surrogate marker to estimate hepatic steatosis in subjects in the community setting if the determination of CAP is not available.

Our study also evaluated the relationship between CAP and LS. The correlation between CAP values and LS was very weak, both in the group of subjects with metabolic risk factors and in the overall population of subjects. In this context, it is important to remind that our
population was composed of subjects from the community setting in which, contrarily to that of the hospital setting, the prevalence of increased LS is low. However, a closer look at individual values of CAP and LS showed that increased LS was almost exclusively observed in patients with high CAP values indicative of severe steatosis. Of interest, none of the subjects from the control group had increased LS despite the fact that some of them had relatively high CAP values, yet lower than those in the metabolic risk group. The number of subjects with histological examination was relatively low. In some subjects, significant liver fibrosis was confirmed (from F2 to F4), whereas in others there was only steatosis without significant liver fibrosis. This lack of fibrosis in some subjects may be related to the fact that steatosis “per se” may
increase LS values [31]. The possibility of a sampling error in liver biopsy also exists yet it is difficult to prove. Recent studies have demonstrated that the presence of steatosis increases LS and therefore the cut-off level for significant liver fibrosis in patients with NAFLD should be around 9kPa, higher than that in other disease states such as viral hepatitis [23,32]. The relationship between LS and CAP values has been investigated in great detail in a recent study by Karlas et al which analyzed a very large population of patients with different etiologies of chronic liver disease and from different geographical areas [33]. Overall, the study showed that CAP has a small impact on classification of patients with significant fibrosis according to LS. In populations with low prevalence, consideration of CAP can improve slightly the already high negative predictive value of LS in ruling out significant liver fibrosis. Moreover, the study confirmed that the accuracy of LS for detecting significant liver fibrosis is limited, due to high rate of false-positive values, particularly in patients with large CAP values [33]. As an example, in our study 3 subjects who underwent a liver biopsy for LS > 14 kPa and who had CAP values ≥350 dB/m did not have fibrosis in the liver biopsy.

The findings of the current study also provide interesting information with respect to potential screening strategies for liver fibrosis related to NAFLD in primary care [34,35]. Our results support that screening should be focused in subjects with metabolic risk factors and that subjects without metabolic risk factors should not be screened because of very low probability of significant liver fibrosis. In fact, none of the subjects without metabolic risk factors included in the study had increased LS. Interestingly, a recent large population-based study showed that the prevalence of LS >9.2kPa among subjects without risk factors was of only 0.4%, compared to 5.4% in subjects with risk factors [23].

The present study has several strengths: 1/ it is population-based; patients were randomly selected from subjects attending a primary care center; 2/ both the M and XL probes of the Fibroscan system were used; this allowed acquiring reliable measurements in the majority of subjects included in the study despite a high proportion of obese patients; and 3/ a control group of subjects without metabolic risk factors was evaluated for comparison. However, the study has also some limitations that should be mentioned: 1/ liver histology should ideally have been obtained in a higher proportion of patients to correlate histological findings with CAP values; however, although this may be feasible in series of patients from hospital care, this is unrealistic in the setting of primary care, where the acceptability of invasive procedures is very low in relatively healthy populations; 2/ the study was performed in a single primary care center of an urban area; therefore, results would require validation in other primary care centers, also from non-urban areas; and 3/ the sample size is relatively low and results should ideally be validated in larger subject populations.

In conclusion, almost half of subjects with metabolic risk factors with unknown liver disease status seen in primary care have increased values of CAP, indicative of moderate-to-severe steatosis. FLI could be used as a surrogate marker of CAP in primary care because of good correlation between the two variables. Significant liver fibrosis was only found in subjects with metabolic risk factors and associated high CAP values, yet the frequency of liver fibrosis found was lower compared to that in previous studies.

**Acknowledgments**

The authors would like to acknowledge the secretarial support of Nicki van Berckel and Roser Poblet. The authors would like to thank also all subjects who participated in the study.

The study was supported by grants from the Instituto de Salud Carlos III through the Plan Estatal de Investigación Científica y Técnica y de Innovación 2013–2016, project reference PI 12/00330 and PI 16/00043. This grant is co funded by the European Regional Development
Fund (ERDF) (FEDER). The study is also supported by the Agencia de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) 2014/SGR 708. Pere Ginès is recipient of an ICREA Academia Award.

Author Contributions

Conceptualization: Núria Fabrellas, Rosario Hernández, Isabel Graupera, Elsa Solà, Consuelo Simón, Carmina Olivé, Pere Ginès.

Data curation: Núria Fabrellas, Rosario Hernández, Pilar Ramos, Natividad Martín, Alicia Coiduras, Isabel Duaso, Angel Casado, Julian Martín, Marta Ginès, Nuria Moreno, Ana Gema Perez, Laia Marti, Mireia Bernat, Montse Sola.

Formal analysis: Núria Fabrellas, Rosario Hernández, Adrià Juanola, Pere Ginès.

Funding acquisition: Isabel Graupera.

Investigation: Núria Fabrellas, Elsa Solà, Consuelo Simón, Teresa Graell, Ana de la Arada, Alicia Coiduras, Isabel Duaso, Angel Casado, Julian Martín, Marta Ginès, Nuria Moreno, Laia Marti, Montse Sola, Carmina Olivé, Pere Ginès.

Methodology: Núria Fabrellas, Rosario Hernández, Elsa Solà, Natividad Martín, Almudena Pérez, Andrea Larrañaga, Manel Garcia, Adrià Juanola, Carmina Olivé, Cristina Solé.

Resources: Pilar Ramos, Natividad Martín, Gemma Sáez, Almudena Pérez, Teresa Graell, Andrea Larrañaga, Manel García, Ana de la Arada, Cristina Solé.

Software: Pilar Ramos, Gemma Sáez.

Supervision: Rosario Hernández, Isabel Graupera, Carmina Olivé, Cristina Solé.

Validation: Isabel Graupera, Elsa Solà, Pilar Ramos, Consuelo Simón, Almudena Pérez, Teresa Graell, Andrea Larrañaga, Manel Garcia, Ana de la Arada, Alicia Coiduras, Angel Casado, Julian Martín, Marta Ginès, Nuria Moreno, Ana Gema Perez, Laia Marti, Mireia Bernat, Montse Sola, Cristina Solé.

Visualization: Pilar Ramos, Teresa Graell, Andrea Larrañaga, Manel García, Ana de la Arada, Adrià Juanola, Alicia Coiduras, Isabel Duaso, Angel Casado, Julian Martín, Marta Ginès, Nuria Moreno, Ana Gema Perez, Mireia Bernat, Cristina Solé.

Writing – original draft: Núria Fabrellas, Rosario Hernández, Isabel Graupera, Gemma Sáez, Marta Ginès, Pere Ginès.

Writing – review & editing: Núria Fabrellas, Rosario Hernández, Isabel Graupera, Elsa Solà, Adrià Juanola, Alicia Coiduras, Isabel Duaso, Angel Casado, Julian Martín, Nuria Moreno, Ana Gema Perez, Laia Marti, Mireia Bernat, Montse Sola, Carmina Olivé, Pere Ginès.

References

1. Diehl AM, Day C. Cause, pathogenesis, and treatment of non-alcoholic steatohepatitis. New Engl J Med 2017; 377:2063–72. https://doi.org/10.1056/NEJMra1503519 PMID: 29166236

2. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64:73–84. https://doi.org/10.1002/hep.28431 PMID: 26707365

3. Satapathy SK, Sanyal AJ. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. Semin Liver Dis 2015; 35:221–35. https://doi.org/10.1055/s-0035-1562943 PMID: 26379640

4. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for

PLOS ONE | https://doi.org/10.1371/journal.pone.0200656 September 18, 2018 16 / 18
23. Ll Caballeria, Pera G Arteaga, Rodriguez L, Aluma A, Morillas RM, et al. High prevalence of liver fibrosis among European adults with unknown liver disease. A population-based study. Clin Gastroenterol Hepatol 2017; 15:1557–65. https://doi.org/10.1016/j.cgh.2016.08.015 PMID: 27445327

22. Yoneda M, Yoneda M, Mawatari H, Fujuta K, Endo H, Lida H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008; 40:371–8. https://doi.org/10.1016/j.dld.2007.10.019 PMID: 18083083

21. Lupsum M, Badea R, Stefanescu H, Grigorescu M, Serban A, Radu C, et al. Performance of unidimensional transient elastography in staging of non-alcoholic steatohepatitis. J Gastroenterin Liver Dis 2010; 19:53–60. PMID: 20361076.

20. Li Caballeria, Pera G Arteaga, Rodriguez L, Aluma A, Morillas RM, et al. High prevalence of liver fibrosis among European adults with unknown liver disease. A population-based study. Clin Gastroenterol Hepatol 2017; 15:1557–65. https://doi.org/10.1016/j.cgh.2016.08.015 PMID: 27445327

19. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, Blood Institute Scientific Statement. Circulation 2005; 112:666–75. https://doi.org/10.1161/01.CIR.105.10.666 PMID: 16157785

18. Bedogni G, Bellanti S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6:33. https://doi.org/10.1186/1471-230X-6-33 PMID: 17081293

17. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, Blood Institute Scientific Statement. Circulation 2005; 112:666–75. https://doi.org/10.1161/CIRCULATIONAHA.105.169404 PMID: 16157785

16. Younossi Z, Henry L. Contribution of alcoholic and non-alcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology 2016; 150:1778–85. https://doi.org/10.1053/j.gastro.2016.03.005 PMID: 26980624

15. Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology 2017; 65:1736–45. https://doi.org/10.1002/hep.29085 PMID: 28130788

14. Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Looma R. Fibrosis progression in nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol 2015; 13:643–51. https://doi.org/10.1016/j.cgh.2014.04.014 PMID: 24768810

13. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but No Other Histologic Features, Is Associated With Long-Term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2015; 149:389–97. https://doi.org/10.1053/j.gastro.2015.04.043 PMID: 25935633

12. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64:1388–402. https://doi.org/10.1016/j.jhep.2015.11.004 PMID: 27062661

11. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67:328–57. https://doi.org/10.1002/hep.29367 PMID: 28714183

10. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64:1388–402. https://doi.org/10.1016/j.jhep.2015.11.004 PMID: 27062661

9. Castera L, Vilgrain V, Anguo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10: 666–75. https://doi.org/10.1038/nrgastro.2013.175 PMID: 24061203

8. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129:113–21. https://doi.org/10.1053/j.gastro.2005.04.014 PMID: 16012941

7. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64:1388–402. https://doi.org/10.1016/j.jhep.2015.11.004 PMID: 27062661

6. Diehl AM, Day C. Cause, pathogenesis and treatment of non-alcoholic steatohepatitis. New Engl J Med 2017; 377:2063–72. https://doi.org/10.1056/NEJMra1503519 PMID: 29166236

5. Younossi Z, Henry L. Contribution of alcoholic and non-alcoholic fatty liver disease to the burden of liver-related morbidity and mortality. Gastroenterology 2016; 150:1778–85. https://doi.org/10.1053/j.gastro.2016.03.005 PMID: 26980624

4. Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-Term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology 2015; 149:389–97. https://doi.org/10.1053/j.gastro.2015.04.043 PMID: 25935633

3. Berzigotti A. Getting closer to a point-of-care diagnostic assessment in patients with chronic liver disease: controlled attenuation parameter for steatosis. J Hepatol 2014; 60:910–2. https://doi.org/10.1016/j.jhep.2014.01.017 PMID: 24486330

2. Bedogni G, Bellanti S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 2006; 6:33. https://doi.org/10.1186/1471-230X-6-33 PMID: 17081293

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, Blood Institute Scientific Statement. Circulation 2005; 112:2735–52. https://doi.org/10.1161/CIRCULATIONAHA.105.169404 PMID: 16157785
24. Sasso M, Beaugrand M, de Ledinghen B, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol 2010; 36:1825–35. https://doi.org/10.1016/j.ultrasmedbio.2010.07.005 PMID: 20870345

25. Karlas T, Petroff D, Sasso M, Mi YQ, de Ledinghen, Kumor V et al. Individual patient-data meta-analysis of controlled attenuation parameter (CAP) for assessing steatosis. J Hepatol 2017; 66(15): 1022–1030

26. Schawbel P, Bota S, Salzl P, Mandonfer M, Payer BA, Ferlitsch A, et al. New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. Liver Intern 2015; 35:381–90. https://doi.org/10.1111/liv.12623 PMID: 24953516.

27. Wong VW1, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010; 59:969–74. https://doi.org/10.1136/gut.2009.205088 PMID: 20581244.

28. McPherson S1, Hardy T2, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-Steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol. 2015 62:1148–55. https://doi.org/10.1016/j.jhep.2014.11.034 PMID: 25477264

29. Armstrong MJ, Houlihan DD, Newsome PN. NAFLD is underrecognized in the primary care setting: UK experience. Am J Gastroenterol 2014; 109:1500–1. https://doi.org/10.1038/ajg.2014.207 PMID: 25196882

30. Blais P, Husain N, Kramer JR, Kowalkowski M, El-Serag H, Kanwal F. Nonalcoholic fatty liver disease is underrecognized in the primary care setting. Am J Gastroenterol 2015; 110_10–4. https://doi.org/10.1038/ajg.2014.134 PMID: 24890441

31. Petta S, Wong VW, Cammà C, et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. Hepatology 2017; 65:1145–55. https://doi.org/10.1002/hep.28843 PMID: 27639088

32. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61:409–15. https://doi.org/10.1136/gutjnl-2011-300342 PMID: 21846782

33. Karlas T, Petroff D, Sasso M, et al. Impact of controlled attenuation parameter in detecting fibrosis using liver stiffness measurement. Aliment Pharmacol Ther 2018; 47:989–1000 https://doi.org/10.1111/apt.14529 PMID: 29446106

34. Ginès P, Graupera I, Lammert F, et al. Screening for liver fibrosis in the general population: a call for action. Lancet Gastroenterol Hepatol 2016; 1:256–60. https://doi.org/10.1016/S2468-1253(16)30081-4 PMID: 28404098

35. Harris R, Harman DJ, Card TR, Aithal GP, Guha IN. Prevalence of clinically significant liver disease within the general population, as defined by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol 2017; 2:288–97. https://doi.org/10.1016/S2468-1253(16)30205-9 PMID: 28404158